Contemporary Guidelines for Menopausal Health

Menopausal care has undergone a significant transformation over the past two decades, evolving from a symptom-centric approach to a comprehensive, evidence-based, and individualized model of care. This shift has been driven by advances in clinical research, an enhanced understanding of women’s health needs, and a global movement toward personalized patient care. Clinical Practice Guidelines (CPGs) have been central to this progress, emphasizing shared decision-making, risk stratification, and the appropriate timing and route of therapy rather than uniform treatment algorithms. This supplement of the Indian Menopause Society’s CPGs aims to translate this evolving evidence into pragmatic care pathways applicable across India’s diverse healthcare settings.[1,2] Guidelines are rigorously developed, evidence-based statements that guide clinicians and patients toward informed decision-making in specific clinical scenarios. In menopausal care marked by heterogeneity in symptoms, cultural perceptions, and risk profiles, such guidelines offer a dependable, structured, and adaptable framework to support optimal clinical practice. Medical guidelines ensure quality, consistency, and safety in clinical care. By consolidating available evidence, evaluating benefits and harms, and presenting pragmatic recommendations, guidelines help reduce practice variation and promote high-quality, standardized management. They improve patient outcomes by endorsing effective interventions – such as menopausal hormone therapy (MHT) for vasomotor symptoms and also showing drawbacks. The role of lifestyle medicine is also gaining its due place in the menopause toolkit.[3] From a health systems perspective, guidelines contribute to cost-effective care by helping clinicians choose appropriate investigations and treatments. They also provide medicolegal protection by offering rational, research-backed pathways for decision-making. For clinicians, guidelines are an invaluable tool for continuous professional development, particularly in rapidly evolving fields of menopausal medicine.[4] Managing menopause is a global issue with local realities. Menopause is a physiological milestone with profound implications for a woman’s physical, psychological, and metabolic health. The post-Women’s Health Initiative era led to major paradigm shifts in understanding the benefits and risks of MHT, prompting updated guidelines worldwide.[5] While international guidelines draw upon evidence from large multicentric cohorts, Indian guidelines contextualize these recommendations to suit the unique demographic, nutritional, and epidemiological landscape of Indian women. Earlier menopause, higher metabolic risk, Vitamin D deficiency, and varied access to healthcare necessitate tailored recommendations. Periodical updates improve credential of guidelines. Let us review major international guidelines. The North American Menopause Society (NAMS), 2023: The NAMS statement emphasizes individualized therapy, confirming that MHT remains the most effective treatment for vasomotor symptoms. It endorses the timing hypothesis, supports low-dose and transdermal regimens to minimize risk, and highlights nonhormonal alternatives for women with contraindications.[6] International Menopause Society, 2024 advocates a holistic approach, integrating lifestyle modifications, cardiovascular risk screening, and shared decision-making. Regular re-evaluation of therapy every 1–2 years is recommended. National Institute for Health and Care Excellence Guidelines (UK), NG23 Updated 2024: NICE prioritizes patient-centered counseling and risk assessment. Key features include MHT for vasomotor and urogenital symptoms, transdermal preparations for women at venous thromboembolism risk, and no mandatory age-based discontinuation.[7] European Menopause and Andropause Society (EMAS), 2023: EMAS focuses on cardiometabolic and bone health, encourages micronized progesterone and nonoral estrogen, and promotes multidisciplinary menopausal care. European Society of Endocrinology, 2025: The Endocrine Society supports MHT for specific symptomatic patients and for premature ovarian insufficiency until the physiological age of menopause and highlights the protective effects of early initiation. INDIAN GUIDELINES Indian Menopause Society, 2019 and 2023: Indian guidelines reflect the reality of earlier menopause (